NCT01133288

Brief Summary

This study is to evaluate the safety of Yulex gloves when used by individuals who have documented allergy to natural rubber latex from Hevea brasiliensis. Yulex is a latex from a different plant (Guayule) and in previous studies shows no cross-reactivity to Hevea latex and has not been allergenic in workers exposed to Yulex. The FDA has approved Yulex gloves for use in the general population and has recognized and labeled these gloves as Hevea Latex-free. The labeling still includes a precaution that Yulex gloves may pose a risk for development of allergy because Yulex does contain a small amount of Guayule protein. Yulex Corporation has proposed doing further studies to demonstrate safety and lack of allergenicity in a population that is prone to latex allergy. In the proposed pilot study, the investigators goal is to complete the protocol on 10 adults with spina bifida who are allergic to natural rubber latex who will wear Yulex gloves as part of their regular bladder and bowel care for approximately 30 minutes daily over a 3 month period. The investigators anticipate that the investigators will need to recruit and enroll up to 50 study participants to achieve a final sample of 10 adults with complete study data. Individuals with a history of anaphylaxis will be excluded from the study. The study participants will be tested for Yulex allergy by Glove Puncture Test as well as serology at the beginning and end of the study. The FDA Devices group has reviewed the study design and agreed that this is a suitable first pilot study.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2009

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

May 26, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 28, 2010

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
6 months until next milestone

Results Posted

Study results publicly available

December 23, 2011

Completed
Last Updated

December 23, 2011

Status Verified

November 1, 2011

Enrollment Period

2 years

First QC Date

May 26, 2010

Results QC Date

July 11, 2011

Last Update Submit

November 21, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Sensitization to Yulex

    The primary study outcome will be an assessment for sensitization to Yulex as determined by serological assay for Guayule-specific IgE antibodies. The development of a detectable IgE immune response will be considered a positive study.

    Approximately 3 months

Secondary Outcomes (1)

  • Immune Response to Yulex

    3 months

Interventions

Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (\~30 minutes per day) over a 3 month period.

Also known as: Yulex Natural Rubber Examination Gloves, Powder-Free, FDA 510(k) Number: K063810

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Individuals with spina bifida between the ages of 18 and 60 who exhibit positive serology to latex (Hevea Brasiliensis).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hugo W. Moser Research Institute at Kennedy Krieger Inc.

Baltimore, Maryland, 21205, United States

Location

MeSH Terms

Conditions

Spinal DysraphismLatex Hypersensitivity

Condition Hierarchy (Ancestors)

Neural Tube DefectsNervous System MalformationsNervous System DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHypersensitivityImmune System Diseases

Limitations and Caveats

The study was not completed because funding was never received. The two (2/7)enrolled participants who met screening eligibility criteria were terminated early without receiving the yulex glove intervention.

Results Point of Contact

Title
Eric Levey, M.D.
Organization
Kennedy Krieger Institute

Study Officials

  • Eric B Levey, M.D

    Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research assistant/co-investigator

Study Record Dates

First Submitted

May 26, 2010

First Posted

May 28, 2010

Study Start

July 1, 2009

Primary Completion

July 1, 2011

Study Completion

July 1, 2011

Last Updated

December 23, 2011

Results First Posted

December 23, 2011

Record last verified: 2011-11

Locations